TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7027750
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose and divided dose regimes
Study: 31634870
Drug: Silymarin 140
Normalized name: silymarin 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140 mg every 8 hours for 7 days
Study: 31634870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard treatments
Study: 31043521
Drug: Balovaptan 4
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balovaptan 4 mg
Study: 31043521
Drug: Balovaptan 10
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balovaptan 10 mg
Study: 25482469
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of 20 mL bupivacaine 0.25%
Study: 25482469
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (20 mL saline 0.9%)
Study: 16131291
Drug: Stimulation acupressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation acupressure treatment
Study: 16131291
Drug: Relaxation acupressure
Normalized name: ACUPRESSURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation acupressure treatment
Study: 23981104
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg (one to three times daily)
Study: 18548841
Drug: Ketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.2 mL injection)
Study: 18548841
Drug: Placebo (buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (buffered isotonic saline, 155 mmol/L)
Study: 16800990
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no specific medicine)
Study: 10550755
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 20 mg twice a day
Study: 10550755
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 60 mg twice a day
Study: 10550755
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 120 mg twice a day
Study: 10550755
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 240 mg twice a day
Study: 9479614
Drug: d,l-fenfluramine (FEN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-fenfluramine (FEN) 60 mg
Study: 9479614
Drug: drug-free unipolar
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug-free unipolar patients
Study: 7524593
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor plasma concentrate 3000 U i.v.
Study: 3555690
Drug: Dipyridamole 200
Normalized name: dipyridamole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 200 mg b.d. for 48 h pre-operatively and dipyridamole 200 mg b.d. with aspirin 300 mg daily for 6 weeks after surgery
Study: 3555690
Drug: Prosthetic dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prosthetic dipyridamole and aspirin group
Study: 3555690
Drug: Dipyridamole and
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole and aspirin group
Study: 30753323
Drug: Cashew nut
Normalized name: Cashew nut
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cashew nut phase (1.5 servings or 42 g of cashews/day)
Study: 29102979
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg once daily
Study: 20015430
Drug: Tunnel thread-drawing
Normalized name: Drawing Salve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tunnel thread-drawing therapy
Study: 17047542
Drug: Manual Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Physical Therapy, Exercise, and Walking Group
Study: 15008862
Drug: Polidocanol (POL)
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol (POL) 0.25% solution
Study: 9215605
Drug: Itasetron hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itasetron hydrochloride (0.5, 1, 2, 4, and 8 mg twice daily)
Study: 9215605
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg twice daily)
Study: 3301986
Drug: Polymerized ragweed
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymerized ragweed (PRW) immunotherapy, 15 weekly injections totaling 1359 allergy units
Study: 3301986
Drug: Polymerized ragweed
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymerized ragweed (PRW) immunotherapy
Study: 18705320
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO), started 3 days after operation
Study: 18705320
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HBO treatment)
Study: 12831383
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care buprenorphine treatment
Study: 12831383
Drug: Specialist clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist clinic buprenorphine treatment
Study: 8156354
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 mg every 8 h
Study: 26255876
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for excessive gingival exposure by septum cartilage reinforcement and additional extension using an autologous cartilage graft or ePTFE implant.
Study: 23893461
Drug: Trametinib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (2 mg) administered in a fed state
Study: 23893461
Drug: Trametinib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (2 mg) administered in a fasted state
Study: 17000959
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 44 microg subcutaneously three times weekly (TIW)
Study: 17000959
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 22 microg subcutaneously three times weekly (TIW)
Study: 11097538
Drug: Intraoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative morphine (0.1 mg x kg(‐1))
Study: 11097538
Drug: Postoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative morphine (0.1 mg x kg(‐1))
Study: 8760978
Drug: PTA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTA plus medical treatment (n = 30)
Study: 8760978
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (control group, n = 32)
Study: 1581268
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with epinephrine (5 micrograms/ml)
Study: 1581268
Drug: Unilateral pleural
Normalized name: PLEURAL DRAINAGE KIT ROCKET #51411
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral pleural infusion of bupivacaine
Study: 1581268
Drug: Bilateral pleural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral pleural infusion of bupivacaine
Study: 27129118
Drug: SFDAC intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFDAC intranasal spray (up to 3,200 µg)
Study: 22121129
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg + MTX (Group 3)
Study: 19945102
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with an angular stable interlocking implant (25 patients)
Study: 19945102
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (25 patients)
Study: 17380402
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation consisting of an isotonic solution containing polyethylene glycol and simethicone (200 ml given 30 min before capsule, followed by 100 ml of prep and 100 ml of water; additional 100 ml of prep given 45 and 75 min later)
Study: 17380402
Drug: Control administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control administration of 100 ml of water and no simethicone
Study: 10434485
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at an average dose of 0.5 mg/kg twice daily
Study: 8871266
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg twice-a-day
Study: 2273545
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride 2 mg in 8 ml of normal saline administered epidurally one to two hours before the end of surgery.
Study: 2273545
Drug: Morphine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administered epidurally at different spinal levels (Th11-12, L2-3, caudal).
Study: 2273545
Drug: Morphine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administered epidurally.
Study: 6104564
Drug: Primidolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidolol (50 mg or 100 mg)
Study: 27836933
Drug: Regorafenib (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (starting doses: 160 mg or lower)
Study: 27836933
Drug: Regorafenib (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (lower dose)
Study: 27836933
Drug: Regorafenib (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (overall treatment)
Study: 23298394
Drug: Radiofrequency-induced heat
Normalized name: heather pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency-induced heat therapy (RFHT) for 30-60 seconds
Study: 23298394
Drug: Intralesional sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional sodium stibogluconate (SSG) injections (50 mg cm(‐2) of lesion, seven injections)
Study: 20659937
Drug: Nystatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (1 ml suspension, 100,000 U/ml, every 8 h)
Study: 20659937
Drug: Fluconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (3 mg/kg body weight, every third day)
Study: 19074465
Drug: LB03002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 at 0.2 mg/kg
Study: 19074465
Drug: LB03002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 at 0.5 mg/kg
Study: 19074465
Drug: LB03002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 at 0.7 mg/kg
Study: 19074465
Drug: LB03002 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 at all doses
Study: 17685721
Drug: Tapering (TAP)
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering (TAP) for 4 weeks
Study: 15050497
Drug: No rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rescue treatment (Control)
Study: 11720096
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MDMA (first dose)
Study: 11720096
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MDMA (second dose, 4 hours after first)
Study: 11720096
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MDMA (second dose, 24 hours after first)
Study: 11720096
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MDMA (two doses, 4 hours apart)
Study: 11720096
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MDMA (two doses, 24 hours apart)
Study: 9340923
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (estrogen replacement therapy)
Study: 3479456
Drug: Adjunctive irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive irrigation with chlorhexidine or hydrogen peroxide
Study: 18270832
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (2.5 mg and higher)
Study: 15523305
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unfractionated heparin or enoxaparin + IIb/IIIa inhibition
Study: 15523305
Drug: IIb/IIIa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIb/IIIa inhibitors (upstream drug initiation)
Study: 15523305
Drug: IIb/IIIa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIb/IIIa inhibitors (during angioplasty only)
Study: 8374115
Drug: Contrast-enhanced MR
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced MR imaging (CE-MRI) with intravenous application of a contrast agent (0.1 mmol Gd-DTPA/kg)
Study: 17802784
Drug: 4 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of 7+3+VP‐16 and 5 courses of maintenance therapy (7+3 with thioguanin)
Study: 17802784
Drug: 2 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 courses of 7+3+VP‐16, 2 HAD courses, treatment discontinuation
Study: 11816441
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate for 3 days followed by single-dose sulfadoxine-pyrimethamine (Q3 + SP, Group II)
Study: 11816441
Drug: Mefloquine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 20 mg/kg single dose (MEF, Group IV)
Study: 952756
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid in aqueous cream or white soft paraffin at concentrations of 2-12% applied to normal skin.
Study: 25078385
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine (1.5mg/kg bolus at intubation followed by 1.5mg/kg/h infusion until 1h post-surgery)
Study: 9040543
Drug: Energy-dense milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-dense milk cereal formula (5 kJ/g, 11% protein)
Study: 9040543
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (milk-cereal formula with 2.5 kJ/g, 11% protein)
Study: 30590877
Drug: 1.2-g LCPUFA-ω3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2-g LCPUFA-ω3 daily for 3 months
Study: 30590877
Drug: 1-g sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g sunflower oil daily for 3 months (Control)
Study: 20801942
Drug: Systematic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic treatment programme (experimental group)
Study: 20801942
Drug: Routine occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine occupational therapy (control group)
Study: 17375319
Drug: Early onset
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early onset cognitive behavioural therapy
Study: 17375319
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no early onset cognitive behavioural therapy)
Study: 25386453
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 μg/kg body weight) oral in a single dose
Study: 25386453
Drug: Topical Permethrin
Normalized name: permethrin Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Permethrin 5% cream single application
Study: 25386453
Drug: Topical gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gamma benzene hexachloride (GBHC) lotion 1% single application
Study: 25386453
Drug: Topical Benzyl
Normalized name: benzyl alcohol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Benzyl benzoate (BB) lotion 25% single application
Study: 23033919
Drug: Supplement (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (120 mg of N-oleyl-phosphatidyl-ethanolamine and 105 mg of epigallocatechin-3-gallate)
Study: 15105028
Drug: Supplement
Normalized name: fat supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement
Study: 17324047
Drug: 30-mg cortisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg cortisol
Study: 9568442
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy for H. pylori
Study: 8092559
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate 100 micrograms twice daily
Study: 8092559
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (200 micrograms once daily or 100 micrograms twice daily)
Study: 2964468
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no-treatment group)
Study: 27457469
Drug: Latanoprostene bunod
Normalized name: Latanoprostene bunod
DrugBank: Latanoprostene bunod (DB11660)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latanoprostene bunod (LBN) ophthalmic solution 0.024%
Study: 25885543
Drug: Qishe pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishe pill (3.75 grams)
Study: 25885543
Drug: Qishe pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishe pill (7.5 grams)
Study: 25885543
Drug: Qishe pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishe pill (15 grams)
Study: 15181134
Drug: Thyroglobulin (Tg)
Normalized name: thyroglobulin
DrugBank: Thyroglobulin (DB01584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroglobulin (Tg) levels measured just before (131)I ablative therapy (Tg1)
Study: 9323144
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy and continuous-course radiotherapy (Arm B)
Study: 8457239
Drug: Nimesulide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (200 mg suppository, t.i.d. for 2 days)
Study: 8457239
Drug: Paracetamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (500 mg suppository, t.i.d. for 2 days)
Study: 20405515
Drug: Methylprednisolone monotherapy
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone monotherapy (MpMT) (32 mg/m2/day IV x 3 days)
Study: 15781794
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) with Soffodex
Study: 15781794
Drug: Non-mechanical bowel
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-mechanical bowel preparation (non-MBP)
Study: 10943959
Drug: Glucose‐ORS (G‐ORS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose‐ORS (G‐ORS)
Study: 1583307
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (200 mg orally, 48 hours before Sulprostone injection)
Study: 1583307
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 treatment
Study: 23348641
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation (G1) with propofol (1mg/kg) and continuous infusion of propofol (25‐50mg/kg/min) and remifentanil (0.01‐0.05 mg / kg / min)
Study: 23348641
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (G2) with propofol (2mg/kg) and continuous infusion of propofol (60‐100mg/kg/min) and remifentanil (0.06 to 0.1g/kg/min)
Study: 20486868
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for 6 months in women without RAAS blockade
Study: 20486868
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for 6 months in women with RAAS blockade
Study: 19064745
Drug: ethyl‐EPA, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethyl‐EPA, 1 g twice a day
Study: 15955148
Drug: Incentive spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive spirometry (IS) for 2 months with medical treatment
Study: 9562208
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus Mianserin
Study: 9562208
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus Placebo
Study: 8572086
Drug: Ineraid cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineraid cochlear implant
Study: 21991809
Drug: rhGMCSF gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGMCSF gel
Study: 21991809
Drug: gel matrix
Normalized name: Sil_k Pad Gel Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel matrix (control group)
Study: 17270384
Drug: Risk factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factor tested (which may be a drug) in case-control studies
Study: 16200777
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rhTPO at doses of 0.25, 0.5, 1.0, and 2.0 microg/kg